Blood test study for multiple myeloma progression
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study is testing whether a blood test that measures a protein called BCMA can help doctors know if your multiple myeloma is getting worse. You may be able to join if your myeloma has come back or not responded to at least two prior treatments, and you have not taken the drug Ruxolitinib before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma that has come back or not responded to at least two prior treatments, including lenalidomide, a proteasome inhibitor, and an anti-CD38 antibody.
- You must have measurable signs of myeloma in your blood or urine.
- You must not have taken the drug Ruxolitinib before.
- You must be well enough to be up and about at least half of the day (ECOG score of 2 or less).
- You must have adequate kidney, liver, and blood cell function according to specific lab tests.
- Females who can become pregnant and males must agree to strict birth control measures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a combination of ruxolitinib plus steroids and lenalidomide in people with relapsed or refractory multiple myeloma. It’s designed for patients who have had at least two prior treatment options and whose myeloma is getting worse or not responding.
This study looks at whether a simple blood test can help track multiple myeloma. It will measure a protein called soluble BCMA that may indicate how active the disease is, potentially helping doctors monitor patients without frequent bone marrow tests.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This study looks at simple blood test results from people newly diagnosed with multiple myeloma to see if those results can help predict how the disease may progress. It aims to find patterns in the blood that might guide future treatment decisions without any extra procedures or drugs.
This study is testing new drugs for people recently diagnosed with multiple myeloma, a blood cancer. It aims to see if the new treatment is safe and effective, and it may offer an additional treatment option.
This early-phase study tests how safe a new drug (CC-92480) is and how much it stays in the body, when given with other standard or study treatments. It’s for people whose multiple myeloma has come back or did not respond after prior therapy, with the goal of improving disease control.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.